title: The effect of royal jelly on CD3(+), CD5(+), CD45(+) T-cell and CD68(+) cell distribution in the colon of rats with acetic acid-induced colitis.
abstract: BACKGROUND
  Traditional medicines and health supplements have historically been used to treat many illnesses but most of them have not been evaluated objectively to prove their efficacy. We have been investigating the effects of royal jelly (RJ) supplements on acetic acid-induced colitis on the distribution of CD3(+), CD5(+), CD45(+) T-cell and CD68(+) cells in rats.
  
  
  METHODS
  The rats were divided into four equal groups: control group, royal jelly-treated (RJ - 150mgkg(-1) body weight), acetic acid-treated (colitis) and acetic acid-treated (colitis)+royal jelly (CRJ - 150mgkg(-1) body weight). Colitis was induced by intracolonic instillation of 4% acetic acid; the control group received physiological saline (10mLkg(-1)). Colon samples were obtained under deep anaesthesia from animals in four groups. Tissues were fixed in 10% formalin neutral buffer solution for 24h and embedded in paraffin.
  
  
  RESULTS
  The proliferative response of CD3(+) and CD45(+) T cells stimulated with colitis was affected by colitis treated with RJ. No differences were found in CD5(+) T cells and CD68(+) macrophages in the colitis treated with RJ.
  
  
  CONCLUSIONS
  This study has shown that RJ has anti-inflammatory and cell regeneration effect in the colon of rats with acetic acid induced colitis.
authors: University of Trakya, Faculty of Medicine, Department of Histology and Embryology, Edirne, Turkey. turankaraca74@hotmail.com
authors: T
authors: T
authors: Karaca
authors: N
authors: N
authors: Şimşek
authors: S
authors: S
authors: Uslu
authors: Y
authors: Y
authors: Kalkan
authors: I
authors: I
authors: Can
authors: A
authors: A
authors: Kara
authors: M
authors: M
authors: Yörük
mesh_terms: D019342:Acetic Acid / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D017252:CD3 Complex / Q000032:analysis; D018956:CD5 Antigens / Q000032:analysis; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000276:immunology*; D003106:Colon / Q000276:immunology*; D005227:Fatty Acids / Q000008:administration & dosage*; D006801:Humans; D017493:Leukocyte Common Antigens / Q000032:analysis; D008264:Macrophages / Q000187:drug effects / Q000276:immunology; D051381:Rats; D011913:Rats, Inbred BB; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D000099219:Royal Jelly; D000097382:CD68 Molecule
chemical_list: D019342:Acetic Acid; D000893:Anti-Inflammatory Agents; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D017252:CD3 Complex; D018956:CD5 Antigens; D005227:Fatty Acids; D017493:Leukocyte Common Antigens; D000099219:Royal Jelly; C067980:CD68 antigen, human; D000097382:CD68 Molecule